Piperidine Market is projected to expand between 4.0% and 6.0% CAGR during the forecast period 2021-2031
Piperidine Market is projected to expand between 4.0% and 6.0% CAGR during the forecast period 2021-2031
Stay updated with breaking news from Life Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Piperidine Market is projected to expand between 4.0% and 6.0% CAGR during the forecast period 2021-2031
Revenues from generic API segment increased 38.3% YoY to Rs 4,803 crore during Q1, driven by growth across all geographies
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸ On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.Read Full Article▸ ...
BARD1 Life Sciences raises $15 million to accelerate cancer diagnostic test development Chairman Dr Geoff Cumming said: “The capital raising was strongly supported by new and existing institutional and sophisticated investors with a deep understanding of the biotechnology sector and importance of early cancer detection on patient outcomes.” Shareholders will be offered the opportunity to participate in a Share Purchase Plan to raise up to a further $2 million. BARD1 Life Sciences Ltd has raised $15 million in a placement to sophisticated, institutional and professional investo...
University of Liverpool signs option agreement with BARD1 for type 3C diabetes test The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd, for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool's Institute of Systems, Molecular and Integrative Biology. There are around 22.9 million new cases of new-onset diabetes diagnosed around the globe. T3cDM diabetes occurs in around 10 per cent of all new-onset diabetes cases. Currently, no test exis...